Question-and-Answer Session
Alright, thank you. [Operator Instructions]. And there is a question from Gregg Gilbert with Merrill Lynch. Please go ahead.
Gregg Gilbert - Merrill Lynch
Thanks, good morning.
Bruce L. Downey, Esq. - Chairman of the Board and Chief Executive Officer
Good morning. Gregg.
William T. McKee - Executive Vice President and Chief Financial Officer
Good morning.
Gregg Gilbert - Merrill Lynch
Two quick questions. Bill, first, can you tell us what gross margin would have look like without Yasmin generic and for Bruce, do you believe your accommodation with Teva will spur other large generic M&A transactions in the near to mid-term? Thanks.
William T. McKee - Executive Vice President and Chief Financial Officer
Gregg, on the margin question, the? an adjusted basis, Ocella had a negative impact of about a little more than a percentage point. So, it reported around 52%. It would have been a little over 53%.
Gregg Gilbert - Merrill Lynch
Thanks.
Bruce L. Downey, Esq. - Chairman of the Board and Chief Executive Officer
Gregg, I didn’t bring my Teva cards this morning, but there’s been a movement for consolidation for the 15 years, I’ve been in business and I think at any point you can say in the near or mid-term you could expect some additional consolidation. I don’t have any particular one in mind, but I would be surprised if something didn’t happen.
Operator
And the next question comes from Ken Cacciatore with Cowen and Company. Please go ahead.
Ken Cacciatore - Cowen and Co.
Hi, guys. Just had a quick question. Bruce if you could comment on Famy Care, Mylan made an announcement yesterday that they have signed them up for oral contraceptives, and any thoughts you had about that company and that threat.
Bruce L. Downey, Esq. - Chairman of the Board and Chief Executive Officer
I don’t think it’s imminent. We have some?we know something about the company and I know they make these products for other parts of the world. As I’ve said all along, it’s very challenging to bring 20 some new products to market. There have been rumors of people going in the business for a long time and the reality is, there have been very few entrants, because it’s challenged. And I don’t expect them to be out any time soon.
Ken Cacciatore - Cowen and Co.
Okay, great. And then just another one on Actiq, Cephalon’s talking about having the risk management program in place around September. Any complications that you think you would have in matching that risk management program and having your own Actiq ready to go ahead of?I know there’s a bit of discrepancy about the FTC agreement or when it expires, but any thoughts about timing behind your own Actiq?
- To read the full transcript on Seeking Alpha, click here »
